← Leaderboards
Michael B Fallon
University Of Alabama At Birmingham
$7,992,553
Attributed
$12,335,824
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,335,824 · 9
By mechanism
R01$5,893,993 · 2
UM1$5,115,102 · 1
R42$989,753 · 1
R03$290,000 · 1
M01$46,976 · 4
Top collaborators
- Zhiyu Dai3 shared
- Steven M Kawut3 shared
- Timothy A Marlowe2 shared
- Hyo-Jin Park2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Sadis Matalon$21,362,558
- Ian Christopher Davis$6,632,717
- David M Pollock$22,398,356
- Patrick Axel Molina$124,150
- Victor M Darley-Usmar$14,665,521
Others in their field
Top investigators on “Cirrhosis”
- Russell E Ware · Duke University$30,715,534
- Hidekazu Tsukamoto · Va Greater Los Angeles Healthcare System$28,844,065
- Anna Mae Elizabeth Diehl · Johns Hopkins University$25,083,421
- Charles M. Rice · Rockefeller University$24,697,583
- Merrill E Gershwin · University Of California At Davis$23,357,355
- Raymond T Chung · Massachusetts General Hospital$18,086,371
Research focus
CirrhosisMedicalHepatopulmonary SyndromeHypoxemiaLungComplicationGasesFundingLiver DiseasesBlood VesselsEffective TherapyCommon Bile Duct StructureLigationIn VivoSignal TransductionAnimal ModelMediatingMonocyteEndothelinFunctional DisorderAmericanCellsCytokineLead
Grant awards (30)
Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome$751,151
R01 · FY2025 · HL · contact PI
Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis$663,777
R42 · FY2025 · DK
Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome$737,804
R01 · FY2024 · HL · contact PI
Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis$325,976
R42 · FY2024 · DK
Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome$762,815
R01 · FY2023 · HL · contact PI
Sorafenib for Hepatopulmonary Syndrome$2,037,215
UM1 · FY2015 · HL
Sorafenib for Hepatopulmonary Syndrome$2,014,988
UM1 · FY2014 · HL
Sorafenib for Hepatopulmonary Syndrome$1,062,899
UM1 · FY2013 · HL
Mediators of Pulmonary Vasodilatation in Liver Disease$297,353
R01 · FY2013 · DK · contact PI
Mediators of Pulmonary Vasodilatation in Liver Disease$308,138
R01 · FY2012 · DK · contact PI
Mediators of Pulmonary Vasodilatation in Liver Disease$308,138
R01 · FY2011 · DK · contact PI
Mediators of Pulmonary Vasodilatation in Liver Disease$371,500
R01 · FY2010 · DK · contact PI
Mediators of Pulmonary Vasodilatation in Liver Disease$163,343
R01 · FY2008 · DK · contact PI
Mediators of Pulmonary Vasodilatation in Liver Disease$121,626
R01 · FY2008 · DK · contact PI
Mediators of Pulmonary Vasodilatation in Liver Disease$290,784
R01 · FY2007 · DK · contact PI
PENTOXIFYLLINE FOR CIRRHOTIC PATIENTS WITH HEPATOPULMONARY SYNDROME$830
M01 · FY2007 · RR · contact PI
HEPATOPULMONARY INVESTIGATIVE GROUP$554
M01 · FY2007 · RR · contact PI
Mediators of Pulmonary Vasodilatation in Liver Disease$299,469
R01 · FY2006 · DK · contact PI
HEPATOPULMONARY INVESTIGATIVE GROUP$13,630
M01 · FY2006 · RR · contact PI
PENTOXIFYLLINE FOR CIRRHOTIC PATIENTS WITH HEPATOPULMONARY SYNDROME$235
M01 · FY2006 · RR · contact PI
Mediators of Pulmonary Vasodilatation in Liver Disease$306,675
R01 · FY2005 · DK
Hepatopulmonary Syndrome Investigative Group$145,000
R03 · FY2005 · DK
HEPATOPULMONARY INVESTIGATIVE GROUP$30,228
M01 · FY2005 · RR
PENTOXIFYLLINE FOR CIRRHOTIC PATIENTS WITH HEPATOPULMONARY SYNDROME$1,499
M01 · FY2005 · RR
Mediators of Pulmonary Vasodilatation in Liver Disease$295,677
R01 · FY2004 · DK
Hepatopulmonary Syndrome Investigative Group$145,000
R03 · FY2004 · DK
MEDIATORS OF PULMONARY VASODILATATION IN LIVER DISEASE$220,990
R01 · FY2003 · DK
MEDIATORS OF PULMONARY VASODILATATION IN LIVER DISEASE$220,990
R01 · FY2002 · DK
MEDIATORS OF PULMONARY VASODILATATION IN LIVER DISEASE$220,990
R01 · FY2001 · DK
MEDIATORS OF PULMONARY VASODILATATION IN LIVER DISEASE$216,550
R01 · FY2000 · DK